

## **Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Köln**

Literaturliste zu den Patienteninformationen „Sortis und andere Statine im Vergleich“ sowie „Zum Wechsel von Sortis auf ein anderes Statin“

*Stand: 18. November 2004*

Bucher HC, Griffith LE, Guyatt G. Systematic review on the risk and benefit of different cholesterol-lowering interventions. *Arterioscler Thromb Vasc Biol* 1999; 19: 187-195.

Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004; 350: 1495-1504.

Colhoun HM, Betteridge DJ, Durrington PM, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004; 364: 685-696.

Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003; 361: 2005–2016.

Corvol JC, Bouzamondo A, Sirol M, et al. Differential effects of lipid-lowering therapies on stroke prevention. A meta-analysis of randomized trials. *Arch Intern Med* 2003; 163: 669-676.

De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. *JAMA* 2004; 292: 1307-1316.

Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998; 279: 1615–1622.

Gami AS, Montori VM, Erwin PJ, et al. Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes. *BMJ* 2003; 326: 528–529.

Gresser U, Gathof BS. Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke. Comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. *Eur J Med Res* 2004; 9: 1-17.

Grundy SM, Cleeman JJ, Merz CN, et al. Coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *J Am Coll Cardiol* 2004; 44: 720-732.

Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360: 7–22.

Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003; 361: 2005-2016.

LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. *JAMA* 1999; 282: 2340–2346.

Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ* 2003; 326: 1423-1427.

Pfeffer MA, Keech A, Sacks FM, et al. safety and tolerability of pravastatin in long term clinical trials: Prospective Pravastatin Pooling (PPP) project. *Circulation* 2002; 105: 2341-2346.

Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. *BMJ* 2000; 321: 983–986.

Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). *Diabetes Care* 1997; 20: 614–620.

Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996; 335: 1001–1009.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1383-1389.

Schwabe U, Paffrath D (Hrsg.). *Arzneiverordnungs-Report 2004. Aktuelle Daten, Kosten, Trends und Kommentare*. Springer Verlag Berlin, 2004.

Schwartz GG, Olson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 2001; 285: 1711-1718.

Serruys P, Feyter P, Macaya C, et al. Fluvastatin for the prevention of cardiac events following successful first percutaneous coronary intervention. *JAMA* 2002; 287: 3215–3222.

Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; 361: 1149–1158.

Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; 360: 1623–1630.

Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 1995; 333: 1301–1307.

The ALLHAT officers and coordinators for the ALLHAT Collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care. *JAMA* 2002; 288: 2998–3007.

The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Program. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998; 339: 1349–1357.